USPTO Art Unit 1645 Prosecution Statistics

Art Unit Information

Art Unit: 1645
Group: 1640
Tech Center: 1600
Total Cases: 15,454
Last Active: November 2024

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18944516BACILLUS STRAINS FOR IMPROVING FEED CONVERSION RATES AND BODY WEIGHT GAIN IN ANIMALSNovember 2024June 2025Allow710NoNo
18895456LACTIPLANTIBACILLUS PLANTARUM EFFECTIVELY INHIBITING MULTI-DRUG-RESISTANT KLEBSIELLA PNEUMONIAE AND USE THEREOFSeptember 2024January 2025Allow410NoNo
18825396MICROBIAL COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASESSeptember 2024February 2025Allow510YesNo
18821883ENTERIC AEROBIZATION THERAPYAugust 2024February 2025Allow510NoNo
18809763STRAIN OF LACTOBACILLUS HELVETICUS CAPABLE OF REMOVING MULTIPLE HEAVY METALS AND APPLICATION THEREOF IN GOAT MILK POWDERAugust 2024March 2025Allow711YesNo
18799714RELAXIN-2 FUSION PROTEINSAugust 2024February 2025Allow601NoNo
18787340LIVE TESTS FOR DIAGNOSIS OF TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY IN ANIMALS AND HUMANSJuly 2024April 2025Allow811YesNo
18768336DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALSJuly 2024February 2025Allow700YesNo
18768920BACILLUS VELEZENSIS COMPOSITIONS AND METHODS OF USE THEREOFJuly 2024February 2025Allow710YesNo
18763332MITIGATION OF CRYPTOSPORIDIOSIS USING HYDROGEN PEROXIDE-GENERATING COMPOSITIONSJuly 2024March 2025Allow800NoNo
18754918IMMUNOREACTIVE PEPTIDESJune 2024October 2024Allow301NoNo
18744293METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIESJune 2024December 2024Allow610YesNo
18741232PURIFIED CAPSULAR POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAEJune 2024June 2025Allow1210NoNo
18738464Probiotic Method and Composition for Maintaining a Healthy Vaginal MicrobiomeJune 2024January 2025Allow810YesNo
18738385STRAIN OF SELENIUM-ENRICHED LACTIPLANTIBACILLUS PLANTARUM KD-2 AND APPLICATIONS IN PREPARING FERMENTED GOAT MILK AND GOAT MILK POWDERJune 2024April 2025Allow1011NoNo
18737799COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLSJune 2024April 2025Abandon1020YesNo
18734806OMPG VARIANTSJune 2024June 2025Allow1200YesNo
18734015MULTIVALENT PNEUMOCOCCAL VACCINESJune 2024March 2025Allow900NoNo
18676470COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLSMay 2024December 2024Allow720YesNo
18666594BACILLUS CALMETTE-GUERIN (BCG) AND ANTIGEN PRESENTING CELLS FOR TREATMENT OF BLADDER CANCERMay 2024September 2024Allow410NoNo
18665018MULTIVALENT OSPA POLYPEPTIDES AND METHODS AND USES RELATING THERETOMay 2024February 2025Allow900NoNo
18664120Cellular Adjuvants for Viral InfectionMay 2024February 2025Allow910NoNo
18664198Cellular Adjuvants for Viral InfectionMay 2024March 2025Allow1010NoNo
18663247CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USEMay 2024May 2025Allow1211NoNo
18662515MICROBIOME RELATED IMMUNOTHERAPIESMay 2024March 2025Allow1010NoNo
18660419IMMUNOGENIC COMPOSITIONS AND USES THEREOFMay 2024June 2025Allow1310NoNo
18659215PH20 Polypeptide Variants, Formulations and Uses ThereofMay 2024November 2024Allow620NoNo
18655708FimH Mutant, Compositions Therewith And Use ThereofMay 2024June 2025Allow1301YesNo
18654243COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND A FUNGICIDEMay 2024April 2025Allow1211YesNo
18704718SYSTEMS AND METHODS FOR INCREASED PRODUCTION OF RECOMBINANT BIOPOLYMERS VIA GENOME ENGINEERING AND DOWNREGULATION OF BASAL EXPRESSIONApril 2024March 2025Allow1021YesNo
18637589METHODS FOR PRODUCING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CARRIER PROTEIN CONJUGATESApril 2024May 2025Allow1320NoNo
18636759HAEMOPHILUS INFLUENZAE SACCHARIDE-CARRIER CONJUGATE COMPOSITIONS AND USES THEREOFApril 2024June 2025Allow1420NoNo
18633691LONG LASTING EFFECT OF NEW BOTULINUM TOXIN FORMULATIONSApril 2024April 2025Allow1210NoNo
18633805DIETARY SUPPLEMENT COMPOSITION FOR TREATING AND MANAGING ACNEApril 2024September 2024Allow510YesNo
18629715NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONSApril 2024January 2025Allow1001NoNo
18624353ANTI-STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODY AND NUCLEIC ACID ENCODING SEQUENCE THEREOF, AND USES OF THE SAMEApril 2024March 2025Allow1211NoNo
18620483Method and System to Modify an Individual�s Gut-Brain Axis to Provide Neurocognitive ProtectionMarch 2024February 2025Allow1010NoNo
18615672Modulation of an Individual's Gut Microbiome to Address Osteoporosis and Bone DiseaseMarch 2024March 2025Allow1120YesNo
18609229Treatment of WartsMarch 2024May 2025Allow1410NoNo
18609596IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS COMPRISING THE SAME AND USES THEREOFMarch 2024June 2025Abandon1510NoNo
18609152METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONSMarch 2024May 2025Allow1410NoNo
18606817ANTIGENIC TRIPEPTIDES DERIVED FROM MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS S-TYPE STRAINS, DERIVATIVES AND USES THEREOFMarch 2024June 2025Allow1511NoNo
18601211COMPLEX OF BOTULINUM NEUROTOXIN E AND ITS BINDING PROTEIN AS A FORMULATION WITH ENHANCED POTENCYMarch 2024March 2025Allow1210YesNo
18599359ANTIBODIES AGAINST MICROORGANISMS AND USES THEREOFMarch 2024June 2025Abandon1601NoNo
18598439STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDES AND IMMUNOGENIC CONJUGATE THEREOFMarch 2024April 2025Allow1310NoNo
18596916ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOFMarch 2024March 2025Allow1210NoNo
18594291COMPOSITIONS FOR USE IN TREATMENT OF CHLAMYDIAMarch 2024November 2024Allow820YesNo
18593739Enhanced Microbial Therapeutic AgentsMarch 2024February 2025Allow1112YesNo
18591306Prevotella Copri CompositionsFebruary 2024April 2025Allow1310NoNo
18590885AGROBACTERIUM FOR REDUCING UPTAKE OF HEAVY METALS BY WHEAT AND USE THEREOFFebruary 2024May 2025Abandon1411NoNo
18589539MICROBIAL COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASESFebruary 2024August 2024Allow510YesNo
18584070METHOD FOR EX-VIVO EXPANSION OF REGULATORY T CELLS WITH ENHANCED SUPPRESSIVE FUNCTION FOR CLINICAL APPLICATION IN IMMUNE MEDIATED DISEASESFebruary 2024May 2025Allow1520NoNo
18442348METHODS OF IMPROVING DESIRABLE TRAITS IN FOWLFebruary 2024June 2025Abandon1601NoNo
18442506CATTLE FEVER TICK-INFESTATION VACCINES AND USES THEREOFFebruary 2024February 2025Allow1210NoNo
18441408PREPARATION OF LIVE VACCINESFebruary 2024April 2025Abandon1410YesNo
18440278MUTANT POREFebruary 2024March 2025Allow1301YesNo
18440212MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDESFebruary 2024May 2025Allow1510NoNo
18437816COMBINATION TREPONEMAL AND NON-TREPONEMAL SYPHILIS TESTFebruary 2024April 2025Allow1510NoNo
18430254ETHYL 2-[9-(2-HYDROXYPYRIDIN-3-YL)-3,6-DIPHENYL-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024March 2025Allow1420NoNo
18424354SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOFJanuary 2024May 2025Allow1511NoNo
18291870METHODS FOR THE REDUCTION OF METHANE PRODUCTION IN RUMINANTSJanuary 2024February 2025Allow1321NoNo
18416083LACTOBACILLUS PARACASEI GLU70 STRAIN WITH GLUTEN-DEGRADING ABILITY AND ANTIBACTERIAL ACTIVITY AND PROBIOTIC PROPERTIES AND USES THEREOFJanuary 2024March 2025Abandon1310NoNo
18412561Probiotic Formulations for the Treatment and Alleviation of Metabolic and Oxidative Stress, Inflammation and NeurodegenerationJanuary 2024May 2025Allow1611YesNo
18409857GUT MICROBES AGAINST INFECTIOUS DISEASES AND ITS USEJanuary 2024February 2025Allow1311NoNo
18407367IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOFJanuary 2024February 2025Allow1411NoNo
18404430SILICIFIED CELL REPLICAS, METHODS OF MAKING, AND METHODS OF USINGJanuary 2024June 2025Allow1710NoNo
18400766METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING SUBJECTS AT RISK FOR POOR CAR T CELL THERAPY RESPONSEDecember 2023February 2025Abandon1410NoNo
18394580COMPOSITIONS AND METHODS FOR GENERATING AN IMMUNE RESPONSE TO TREAT OR PREVENT MALARIADecember 2023February 2025Allow1410NoNo
18394076Foods Providing Probiotic BacteriaDecember 2023February 2025Allow1410NoNo
18393572Lactococcus Bacteria and Uses ThereofDecember 2023January 2025Allow1301YesNo
18392708COMPOSITION FOR SUPPRESSING OR IMPROVING EYE FATIGUEDecember 2023June 2025Allow1821NoNo
18390652COMPOSITIONS AND METHODS FOR INHIBITING SEIZURESDecember 2023March 2025Allow1511YesNo
18544698SLAM POLYNUCLEOTIDES AND POLYPEPTIDES AND USES THEREOFDecember 2023January 2025Allow1310YesNo
18543162ANTI-CD40 ANTIBODIES FOR USE IN TREATING AUTOIMMUNE DISEASEDecember 2023May 2025Abandon1710NoNo
18538064TESTING FOR PARTICULATESDecember 2023January 2025Allow1310NoNo
18537398METHODS AND MATERIALS FOR USING RUMINOCOCCUS GNAVUS OR CLOSTRIDIUM SPOROGENES TO TREAT GASTROINTESTINAL DISORDERSDecember 2023November 2024Allow1110NoNo
18535722TOPICAL APPLICATION TO TREAT ACNE VULGARISDecember 2023November 2024Allow1110NoNo
18536047METHODS AND SYSTEMS FOR DETERMINING PLATELET CONCENTRATIONDecember 2023December 2024Allow1210NoNo
18533453PROBIOTIC BACTERIAL STRAINS PRODUCING ANTIMICROBIAL PROTEINS AND COMPOSITIONS COMPRISING THESE FOR USE IN THE TREATMENT OF DIARRHEAL AND OTHER MICROBIAL DISEASESDecember 2023January 2025Abandon1301NoNo
18532731INFECTIOUS PLASMODIUM SPOROZOITES GROWN IN VITRODecember 2023August 2024Allow810NoNo
18530981Treatment Of Uterine Fibroids Using Purified CollagenaseDecember 2023June 2025Abandon1910NoNo
18528697METHOD FOR THE TREATMENT OF ALLERGIC RHINITISDecember 2023March 2025Allow1610NoNo
18523002ENGINEERED BACTERIA SECRETING THERAPEUTIC PROTEINS AND METHODS OF USE THEREOFNovember 2023September 2024Allow1010NoNo
18519981Combination Method For Treating Or Preventing Childhood Atopic DiseaseNovember 2023July 2024Allow711NoNo
18517327BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF USENovember 2023January 2025Allow1401NoNo
18518137SHEWANELLA DECOLORATIONIS PRODUCING TETRODOTOXIN AND APPLICATION THEREOFNovember 2023August 2024Allow921YesNo
18518117METHODS AND ARRAYS FOR TARGET ANALYTE DETECTION AND DETERMINATION OF TARGET ANALYTE CONCENTRATION IN SOLUTIONNovember 2023May 2025Abandon1820NoNo
18516332MSP NANOPORES AND USES THEREOFNovember 2023January 2025Allow1411NoNo
18513577METHOD OF IDENTIFYING A BIOLOGICALLY-ACTIVE COMPOSITION FROM A BIOFILMNovember 2023March 2025Allow1611NoNo
18510385MONOVALENT VACCINE FORMULATION AND A METHOD FOR PREPARATION THEREOFNovember 2023December 2024Allow1410NoNo
18510369BACILLUS CALMETTE-GUERIN (BCG) AND ANTIGEN PRESENTING CELLS FOR TREATMENT OF BLADDER CANCERNovember 2023April 2024Allow510NoNo
18507264SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATIONNovember 2023February 2025Abandon1501NoNo
18507579IL-1 Receptor Accessory Protein-Inhibiting Antibodies and Antigen-Binding Fragments ThereofNovember 2023May 2024Allow610YesNo
18506072COMPOSITIONS AND METHODS FOR DETECTING PROTEASE ACTIVITY IN BIOLOGICAL SYSTEMSNovember 2023April 2025Abandon1710NoNo
18505504COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOFNovember 2023May 2024Allow600NoNo
18559543CANCER THERAPY WITH LIVE ATTENUATED BACTERIANovember 2023October 2024Allow1110YesNo
18503901LYOPHILIZED AND STABILIZED LIVE ATTENUATED FORMULATED VACCINE AGAINST TULAREMIANovember 2023March 2025Allow1620YesNo
18502728CELL-BASED METHOD FOR DETERMINING AN ACTIVITY OF BOTULINUM TOXINNovember 2023November 2024Abandon1310NoNo
18501825ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTANovember 2023October 2024Allow1122NoNo
18386555ETHYL 2-[9-(2-HYDROXYPYRIDIN-3-YL)-3,6-DIPHENYL-1,8-DIOXO-3,4,9,10- TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUNDNovember 2023February 2024Allow301NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1645.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
137
Examiner Affirmed
89
(65.0%)
Examiner Reversed
48
(35.0%)
Reversal Percentile
62.1%
Higher than average

What This Means

With a 35.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1334
Allowed After Appeal Filing
315
(23.6%)
Not Allowed After Appeal Filing
1019
(76.4%)
Filing Benefit Percentile
13.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1645 - Prosecution Statistics Summary

Executive Summary

Art Unit 1645 is part of Group 1640 in Technology Center 1600. This art unit has examined 15,454 patent applications in our dataset, with an overall allowance rate of 64.8%. Applications typically reach final disposition in approximately 30 months.

Comparative Analysis

Art Unit 1645's allowance rate of 64.8% places it in the 20% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1645 receive an average of 1.92 office actions before reaching final disposition (in the 60% percentile). The median prosecution time is 30 months (in the 41% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.